Josh Wilhelm Joins PetVivo Holdings, Inc. as the Director of Manufacturing
Josh Wilhelm
Director of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”)
MINNEAPOLIS, MN, US, Sept. 08, 2021 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV) (the “Company”) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Josh Wilhelm has accepted a position with the Company as its new Director of Manufacturing.
“We are incredibly fortunate to have secured a manufacturing professional such as Josh who possesses expertise in cGMP manufacturing, process engineering, and quality systems,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Josh is an experienced professional in assembling, coordinating and training manufacturing teams, and has already brought to PetVivo two experienced manufacturing veterans that are currently working with Josh to produce our ground-breaking product, spryng™ for commercial sale.”
Mr. Wilhelm was the Director of Islet Manufacturing and R&D at the Schulze Diabetes Institute (“SDI”), coordinating the islet isolation and research activities of the “Isolation Core”. As the Director of Manufacturing at SDI, Mr. Wilhelm supervised all cGMP manufacturing, process engineering, and quality systems. He further assumed the role at SDI of lead supervisor for human clinical islet manufacturing, managed both clinical and pre-clinical activities of the team and pursued research related to understanding and improving islet isolation yields and islet graft function. Mr. Wilhelm obtained his M.S. in Biomedical Engineering from the University of Minnesota in 2004 and entered industry to explore the real-world application of biomaterials and cell, tissue, and gene therapies for Medtronic, Inc and several local medical device and biotechnology start-ups.
“I am elated at the prospects of leading the manufacturing team of PetVivo, a company whose technology has a multitude of applications that enhance the lives of dogs and horses, as well as humans,” said Mr. Wilhelm. “In the last year, our team of scientists and engineers have organized an extremely safe and efficient system to produce spryng, our therapeutic product for the treatment of arthritis in companion animals. I am looking forward to assisting the Company in meeting the demand for this life-changing product to help animals suffering from osteoarthritis.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
